GDTC - CytoMed Therapeutics Ltd
IEX Last Trade
1.5
0.050 3.333%
Share volume: 4,038
Last Updated: Fri 30 Aug 2024 09:12:46 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.45
0.05
3.45%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-7.42%
1 Month
-18.16%
3 Months
-26.30%
6 Months
-25.94%
1 Year
-57.56%
2 Year
-62.97%
Key data
Stock price
$1.50
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.36 - $5.50
52 WEEK CHANGE
-$0.57
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO:
Region: US
Website:
Employees: 7
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website:
Employees: 7
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
incorporated in 2018, cytomed therapeutics is a spin-off from singapore’s agency for science, technology and research ( a*star) and focuses on translating its patented technologies into gamma delta (γδ) t cell- and natural killer (nk) cell-based “off-the-shelf” immunotherapeutics for a wide range of cancers. we also engage in generating induced pluripotent stem cells (ipscs) and translating them into “off-the-shelf” cellular therapeutics using our proprietary technologies for our customers.
Recent news